What the FDA labels say about taking them together
Disopyramide and insulin aspart
Insulin aspart's FDA label of June 21, 2023 names disopyramide in its drug interactions section; the disopyramide label PlainMeds reads does not name insulin aspart. The insulin aspart label: “Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline …”
Check it at the source: the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc); the insulin aspart FDA label on DailyMed (effective June 21, 2023, Novo Nordisk).
What does the disopyramide label say about insulin aspart?
Disopyramide's label (effective August 24, 2026) does not name insulin aspart in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed
What does the insulin aspart label say about disopyramide?
Insulin aspart label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose reductions and increased frequency of glucose monitoring may be required when FIASP is co-administered with these drugs.
Source: FDA drug label (Insulin Aspart, BLA020986), Novo Nordisk Pharma, Inc., effective February 28, 2023 (SPL set bee5b358-c863-420b-be73-ced2e920c499), via openFDA
Source: FDA drug label (Fiasp), Novo Nordisk, effective June 21, 2023 (SPL set 834e7efc-393f-4c55-9125-628562a8a5cf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Disopyramide | Insulin aspart | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.801 per capsule 100 mg capsule | $6.95 per mL 100 unit/mL vial |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once